Garo Armen Biography and Net Worth

Dr. Garo Armen serves as Chairman and Chief Executive Officer of Agenus Inc., which he co-founded in 1994. Under his leadership, Agenus has been advancing breakthrough scientific technologies and immunotherapeutic products. In addition, Garo oversaw the successful restructuring of the biopharmaceutical company Elan Corporation, plc, where he served as Chairman of the Board of Directors. Garo currently acts as Chairman of the Board of Protagenic Therapeutics, a biotechnology company focusing on human brain hormones for the treatment of neurological and metabolic disorders. He began his research career at Brookhaven National Laboratory subsequent to which he made a transition to Wall Street, as an analyst and investment banker at EF Hutton and then at Dean Witter Reynolds ( now Morgan Stanley) , cultivating key relationships and stock-market expertise. Garo received his PhD in physical chemistry from the City University of New York.

What is Garo H. Armen's net worth?: The estimated net worth of Garo H. Armen is at least $259,773.40 as of February 15th, 2024. Dr. Armen owns 31,298 shares of Agenus stock worth more than $259,773 as of April 25th. This net worth approximation does not reflect any other assets that Dr. Armen may own. Additionally, Dr. Armen receives a salary of $1,340,000.00 as CEO at Agenus. Learn More about Garo H. Armen's net worth.
How old is Garo H. Armen?: Dr. Armen is currently 71 years old. There are 2 older executives and no younger executives at Agenus. Learn More on Garo H. Armen's age.
What is Garo H. Armen's salary?: As the CEO of Agenus Inc., Dr. Armen earns $1,340,000.00 per year. Learn More on Garo H. Armen's salary.
How do I contact Garo H. Armen?: The corporate mailing address for Dr. Armen and other Agenus executives is 3 FORBES ROAD, LEXINGTON MA, 02421. Agenus can also be reached via phone at (781) 674-4400 and via email at [email protected]. Learn More on Garo H. Armen's contact information.
Has Garo H. Armen been buying or selling shares of Agenus?: Garo H. Armen has not been actively trading shares of Agenus in the last ninety days. Most recently, on Thursday, February 15th, Garo H. Armen bought 25,000 shares of Agenus stock. The stock was acquired at an average cost of $13.00 per share, with a total value of $325,000.00. Following the completion of the transaction, the insider now directly owns 31,298 shares of the company's stock, valued at $406,874. Learn More on Garo H. Armen's trading history.
Who are Agenus' active insiders?: Agenus' insider roster includes Garo Armen (CEO), Christine Klaskin (Insider), and Steven O'Day (Insider). Learn More on Agenus' active insiders.
Are insiders buying or selling shares of Agenus?: During the last twelve months, Agenus insiders bought shares 9 times. They purchased a total of 47,628 shares worth more than $893,492.60. The most recent insider tranaction occured on February, 15th when insider Garo H Armen bought 25,000 shares worth more than $325,000.00. Insiders at Agenus own 4.8% of the company. Learn More about insider trades at Agenus.
Information on this page was last updated on 2/15/2024.

Garo H. Armen Insider Trading History at Agenus

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
2/15/2024	Buy	25,000	$13.00	$325,000.00	31,298
9/13/2021	Sell	4,105	$130.00	$533,650.00	42,644
10/30/2017	Buy	5,000	$71.00	$355,000.00
4/12/2017	Buy	5,000	$67.00	$335,000.00	69,451
5/9/2016	Buy	5,000	$63.60	$318,000.00	67,301
3/7/2016	Buy	10,000	$80.60	$806,000.00	62,561
12/29/2015	Sell	10,978	$91.80	$1,007,780.40	52,561
12/28/2015	Sell	6,717	$92.00	$617,964.00	52,561
9/25/2015	Buy	5,000	$100.60	$503,000.00	70,480

Garo H. Armen Buying and Selling Activity at Agenus

Agenus Company Overview

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Today's Range

Now: $8.30

$7.20

$8.47

50 Day Range

MA: $10.97

$4.97

$15.56

2 Week Range

Now: $8.30

$4.78

$42.60

Volume

960,558 shs

Average Volume

628,664 shs

Market Capitalization

$173.89 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.26

Biden replacement revealed?

From Paradigm Press | Ad

A former CIA insider just announced a disturbing prediction… Biden will withdraw as the Democrat nominee on June 13.

See his shocking evidence in this new report

Garo Armen Biography and Net Worth

What is Garo H. Armen's net worth?

How old is Garo H. Armen?

What is Garo H. Armen's salary?

How do I contact Garo H. Armen?

Has Garo H. Armen been buying or selling shares of Agenus?

Who are Agenus' active insiders?

Are insiders buying or selling shares of Agenus?